华蟾素胶囊辅助治疗乳腺癌的系统评价与Meta分析
该研究系统检索七个中英文数据库至2024年10月2日,纳入10项RCT共881例乳腺癌患者,评估华蟾素胶囊辅助治疗的有效性与安全性。Meta分析显示华蟾素胶囊可提高客观缓解率、疾病控制率和KPS改善率,延长无进展生存期与总生存期,调节免疫并降低肿瘤标志物,同时减轻化疗不良反应,但纳入研究方法学质量偏低、证据等级为低或极低。
要点
- 华蟾素胶囊辅助治疗可提高乳腺癌客观缓解率与疾病控制率。
- 可延长无进展生存期与总生存期,并改善KPS体力状况。
- 可调节免疫、降低肿瘤标志物并减轻化疗不良反应。
核心结论
- 华蟾素胶囊作为乳腺癌辅助治疗显示潜在获益,包括增强化疗疗效、改善生活质量、抑制肿瘤进展、延长总生存期、调节免疫功能、降低肿瘤标志物水平及减轻化疗引起的不良事件。
研究设计与样本
- 系统评价与Meta分析,检索七个中英文数据库自建库至2024年10月2日,纳入10项随机对照试验共881例乳腺癌患者。
- 采用ROB 2.0评估方法学质量,RevMan 5.3进行Meta分析,Stata 16.0进行敏感性分析,并用试验序贯分析评估结论可靠性、GRADE方法评价证据质量。
主要发现
- 客观缓解率RR=1.32(95%CI [1.17, 1.49]),疾病控制率RR=1.17(95%CI [1.04, 1.31]),KPS改善率RR=1.54(95%CI [1.18, 2.01])。
- 无进展生存期MD=1.45(95%CI [0.62, 2.28]),总生存期MD=2.75(95%CI [1.66, 3.85])。
- CD3+水平MD=6.28(95%CI [4.95, 7.62]),CD4+水平MD=3.32(95%CI [1.94, 4.70])。
- CEA MD=-1.05(95%CI [-1.50, -0.60]),CA125 MD=-9.89(95%CI [-15.23, -4.55]),CA153 MD=-4.76(95%CI [-6.55, -2.98])。
- 华蟾素胶囊减轻化疗引起的不良反应,包括骨髓抑制、胃肠道反应、白细胞减少和神经损伤。
关键数值与推荐
- 纳入10项RCT共881例受试者,方法学质量普遍偏低,样本量未达到所需信息量。
- 各结局指标的证据质量分级为低或极低。
临床怎么用
- 在乳腺癌化疗基础上可考虑联合华蟾素胶囊以增强疗效、改善体力状况并减轻化疗不良反应,但需结合患者具体情况与证据局限性谨慎决策。
局限性
- 纳入研究方法学质量普遍偏低。
- 样本量未达到试验序贯分析所需的信息量。
- 结局指标证据质量分级为低或极低。
- 研究人群存在固有异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Huachansu capsule (HCSC) is a traditional Chinese patent medicine derived from toad venom (Bufo bufo gargarizans Cantor). In China, HCSC has been widely used as a therapeutic agent for breast cancer (BC). It exerts antitumor effects by inducing apoptosis of BC cells, disrupting the tumor cell cycle, and regulating the immune system. Preliminary clinical studies have confirmed its antitumor efficacy in BC patients. AIM OF THE STUDY: This study aims to systematically evaluate the efficacy and safety of HCSC as an adjuvant therapy for BC. MATERIALS AND METHODS: Seven Chinese and English databases were systematically searched from database inception to October 2, 2024, to identify randomized controlled trials (RCTs) on HCSC for BC treatment. The methodological quality of the included studies was assessed using the revised Cochrane risk of bias tool (ROB 2.0). Meta-analysis was performed using RevMan 5.3, and sensitivity analysis was conducted using Stata 16.0. Trial sequential analysis (TSA) was used to assess the reliability of conclusions regarding the intervention effects, and the certainty of evidence was evaluated using the GRADE approach. RESULTS: A total of 10 RCTs with 881 participants, were included. The meta-analysis revealed that HCSC, as an adjuvant therapy, significantly improved the objective response rate (RR = 1.32, 95 % CI [1.17, 1.49]), disease control rate (RR = 1.17, 95 % CI [1.04, 1.31]), and Karnofsky Performance Status (KPS) improvement rate (RR = 1.54, 95 % CI [1.18, 2.01]). Besides, HCSC prolonged progression-free survival (MD = 1.45, 95 % CI [0.62, 2.28]), overall survival (MD = 2.75, 95 % CI [1.66, 3.85]). The treatment also demonstrated immunomodulatory effects, as indicated by significant increases in CD3+ levels (MD = 6.28, 95 % CI [4.95, 7.62]) and CD4+ levels (MD = 3.32, 95 % CI [1.94, 4.70]). Furthermore, HCSC significantly reduced tumor marker levels, including CEA [MD = -1.05, 95 % CI [-1.50, -0.60]), CA125 (MD = -9.89, 95 % CI [-15.23, -4.55]), and CA153 (MD = -4.76, 95 % CI [-6.55, -2.98]). Regarding adverse events, HCSC ameliorated chemotherapy-induced adverse effects, including myelosuppression, gastrointestinal reactions, leukopenia, and nerve damage. However, the methodological quality of the included studies was generally low, and the sample sizes failed to meet the required information size. The quality of evidence for outcome measures was graded as low or very low. CONCLUSIONS: HCSC as an adjuvant therapy for BC demonstrates potential benefits, including enhancing the efficacy of chemotherapy, improving quality of life, inhibiting tumor progression, prolonging overall survival, modulating immune function, reducing tumor marker levels, and mitigating chemotherapy-induced adverse events. However, given the inherent heterogeneity of study populations and methodological limitations, further high-quality RCTs with larger sample sizes are warranted to validate these findings.
引用
- Wu Q, Xu X, Liu H, et al. Efficacy and safety of Huachansu capsule as adjuvant therapy for breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol. 2025. PMID: 40848904. doi:10.1016/j.jep.2025.120464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。